The Cancer Terminator Foundation™
A breakthrough cure for incurable cancers!
The Cancer Terminator Foundation™ is Here

The Cancer Terminator Foundation is introducing a revolutionary cancer cure to America. Heavy-Ion therapy is now well documented in Europe and Japan as a breakthrough cure for several previously incurable cancers. There is an urgent need for patients in the United States to benefit from this major advance.

The Cancer Terminator Foundation is the new epicenter for research and funding for building Cancer Terminators in America’s most prestigious institutions. The Foundation’s innovative fundraising campaigns will help us achieve our goal of helping to raise one-billion dollars to construct Cancer Terminators in the United States by 2024.

90% of all donations raised will go directly to build Cancer Terminators and provide financial assistance to patients. The Cancer Terminator Foundation is organized and operated for exempt purposes set forth in section 501(c)(3) of the Internal Revenue Code.

“The science community is excited. The world’s leading 40 scientists and physicians specializing in advanced Heavy-ion therapy have come together to create the Cancer Terminator Foundation. An unprecedented group effort is underway to make Heavy-ion therapy available to patients in America and worldwide.

The clinical results from prestigious institutions in Japan and Europe are now well documented. We can cure several incurable cancers. The time is now to build Cancer Terminators in the United States.”

Steven J. Frank, MD
Co-Chairman, Cancer Terminator Foundation.
Medical Director, Director of Advanced Technologies
MD Anderson Cancer Center
This is a Remarkable Advance in Our New Century

“We are very grateful for the vision and hard work of Dr. Steven Frank, MD Medical Director at MD Anderson Cancer Center, Dr. Thomas Buchholz, Medical Director of the Scripps-MD Anderson Department, and Terry Lord of Breakthrough Chronic Care, for making the Cancer Terminator Foundation a reality.”

The Cancer Terminator Foundation is fulfilling a significant need that will save thousands of lives every year. **It is the first foundation to focus 100% of it’s energy and resources to Heavy-Ion therapy.** Our commitment is to make this *miracle machine* available to cancer patients in the United States, and around the world, by 2024.

The clinically proven results are revolutionary in curing many cancers that were previously incurable. The Cancer Terminator Foundation’s mission and execution plan will significantly accelerate the availability of this breakthrough cancer cure to American patients. The Cancer Terminator Foundation has been created by the world’s leading scientists.

**The 40 Co-founders and Scientific Board Members are recognized experts in the exploding field of Heavy-Ion therapy.**
The 40 Co-Founders, Scientific Board Members

The Cancer Terminator Foundation is founded by a driven and collaborative group of world-class scientific researchers who have made this breakthrough cancer cure possible.

Robert L. FOOTE, M.D.
Chair, Radiation Oncology
Mayo Clinic Rochester
USA

Anita MAHAJAN, M.D.
Department of Radiation Oncology
Mayo Clinic Rochester
USA

Oren CAHLON, M.D.
Vice Chair, Dept. Radiation Oncology,
Memorial Sloan Kettering Cancer Center
USA

Simon N. POWELL, M.D., Ph.D.
Chair, Dept. Radiation Oncology,
Memorial Sloan Kettering Cancer Center
USA

Thomas F. DeLANEY, M.D.
Professor Rad. Oncol., Harvard Medical School & Medical Director, Massachusetts General Hospital/Francis H. Burr Proton Therapy Center
USA

Prof. Harald PAGANETTI, Ph.D.
Director of Physics Research,
Dept. of Rad. Oncol., Massachusetts General Hospital & Harvard Medical School
USA

Bhadrasain VIKRAM, M.D.
Chief, Clinical Radiation Oncology Branch
National Cancer Institute
USA

Dr. May ABDEL-WAHAB
Director, Div. Human Health,
International Atomic Energy Agency
AUSTRIA

Prim. Prof. Mag. Dr. Anja BAYERL
Chair, Dept. Radiation Oncology
University Hospital Krems
AUSTRIA

Prof. Jeffrey D. BRADLEY, M.D.
Director, S. Lee Kling Center for Proton Therapy, Washington University School of Medicine
USA

Prim. Doz. Dr. Alexander DE VRIES
Head of Radiation Oncology
State Hospital Feldkirch
AUSTRIA

Prof. Marco DURANTE
Director, Trento Institute for Fundamental Physics and Applications
ITALY

Jay FLANZ, Ph.D.
Chairman, Particle Therapy Co-Operative Group
USA

Dr. Piero FOSSATI
Clinical & Research Director for Carbon Ions,
MedAustron Ion Therapy Center
AUSTRIA

Hesham GAYAR, M.D.
Radiation Oncologist, Karmanos Cancer Institute at McLaren Flint Hospital,
Michigan
USA

Prof. DI Dr. Dietmar GEORG
Professor of Med. Rad. Physics & Oncotechnology
Medical University of Vienna
AUSTRIA

Priv.-Doz. Dr. Petra GEORG
Head of Radiation Oncology & Clinical Studies, MedAustron Ion Therapy Center
AUSTRIA

David GROSSHANS, M.D., Ph.D.
Dept. Radiation Oncology
MD Anderson Cancer Center
USA

Prof. Dr. Jean-Louis HABRAND
Chair, Dept. Radiation Oncology Centre François Baclesse
FRANCE

Prof. Stephen M. HAHN, M.D.
Deputy President & COO
Professor, Div. Radiation Oncology
MD Anderson Cancer Center
USA

Prof. Joseph M. HERMAN, M.D., M.Sc.
Head ad interim, Div. Radiation Oncology
MD Anderson Cancer Center
USA

Prof. Brad S. HOPPE, M.D.
Dept. Rad. Oncol.,
University of Florida Health Proton Therapy Institute
USA
The 40 Co-Founders, Scientific Board Members

Prof. Dr. Oliver JÄKEL
Director, Medical Physics
Heidelberg Ion-Beam Therapy Center
GERMANY

Prof. Tadashi KAMADA, M.D., Ph.D.
Director, General Clinical Research Cluster
Ntl. Institute of Radiological Sciences
JAPAN

Albert C. KOONG, M.D., Ph.D.
Dept. Radiation Oncology
MD Anderson Cancer Center
USA

Prof. Dr. Marco KRENGLI
Chair of Radiotherapy
University of Piemonte Orientale
ITALY

Prof. Dr. Hans LANGENDIJK
Chair of Radiation Oncology
University Medical Center Groningen
NETHERLANDS

Prof. Jiade J. LU, M.D., M.B.A.
Executive Vice President
Shanghai Proton and Heavy-Ion Center
CHINA

Dr. Alejandro MAZAL
Head of Medical Physics Institut Curie
FRANCE

Prof. James M. METZ, M.D.
Chair, Dept. Radiation Oncology,
Abramson Cancer Center, Penn Medicine
USA

Dr. JunEtsu MIZOE
Director
Osaka Heavy-Ion Therapy Center
JAPAN

Prof. Radhe MOHAN, Ph.D.
Dept. Radiation Physics
MD Anderson Cancer Center
USA

Dr. Håkan NYSTRÖM
Chief Physicist, Head of
Skandion Clinic Uppsala
SWEDEN

Prof. Dr. Roberto ORECCHIA
Scientific Director
National Centre of Oncological Hadrontherapy
ITALY

Prof. Ramesh RENGAN, M.D., Ph.D.
Medical Director, SCCA Proton Center,
University of Washington, Seattle
USA

Carl ROSSI, M.D.
Medical Director
California Protons Cancer Therapy Center
USA

Dr. Michael SCHOLZ
Scientific Head of Dept. Biophysics
GSI Helmholtzzentrum für Schwerionenforschung
GERMANY

Prof. Reinhard SCHULTE, M.D.
Div. Biomedical Engineering Sciences
Loma Linda University
USA

Prof. Dr. Felix SEDLMAYER
Chair, University Hospital for Radiotherapy and Rad. Oncol., Salzburg
AUSTRIA

Priv.-Doz. DI Markus STOCK, PhD
Head of Medical Physics
MedAustron Ion Therapy Center
AUSTRIA

Prof. Dr. Beate TIMMERMANN
Medical Director,
West German Proton Therapy Centre Essen
GERMANY

Prof. Dr. Marco VAN VULPEN
Medical Director
Holland Proton Therapy Centre
NETHERLANDS

James W. WELSH, M.D.
Dept. Radiation Oncology
MD Anderson Cancer Center
USA

Prof. Dr. Joachim WIDDER
Chair, Dept. Radiotherapy
Medical University of Vienna
AUSTRIA

Dr. Petra WITT-NYSTRÖM
Specialist physician, Dept. Clinical Oncology
Uppsala University
SWEDEN

Xiaorong Ronald ZHU, Ph.D.
Dept. Radiation Physics
MD Anderson Cancer Center
USA
Revolutionary Cure Rates Are Well Documented
Over 20,000 patients have been treated with the first generation Heavy-Ion therapy in Japan and Europe.

“The first generation of Heavy-Ion therapy has been used with over 10,000 patients in Japan. In many ways the Japanese medical community has been pioneers. The results have been extremely positive. We are curing many cancers that were previously incurable. I am excited about being a co-founder of the Cancer Terminator Foundation and introducing the next generation of Heavy-Ion therapy to the world.”

Dr. JunEtsu Mizoe, Director Osaka Heavy-Ion Therapy Center, JAPAN

“Our institute has used the first generation Heavy-Ion therapy successfully with over 8,000 patients. We believe the next generation of Heavy-Ion therapy is the tipping point in curing many previously incurable cancers. It’s unbelievable that American scientists invented Heavy-Ion therapy, yet this breakthrough cure is not available in America. I applaud the Cancer Terminator Foundation.”

Dr. Thomas Haberer, Scientific Director, Heidelberg Ion-Beam Therapy Center, GERMANY
Primes the Immune System to Attack Metastasized Cancers with Unprecedented Cure Rates.

Brain tumors and tumors at the base of the skull have achieved a 90% five-year survivor rate. Advanced pancreatic cancer results show a two-year survival rate of nearly 50%, this compares to a 5% from traditional treatments. Inoperable chordomas achieve an 85% survival rate that is better than patients who had tumors surgically removed.

50% to 80% cure rates are achieved treating late stage prostate, liver, rectal, lung cancers and for advanced bone and soft tissue sarcomas which have been radiation resistant up until now. Preliminary results in treating advanced colon, breast cancer and additional cancers are extremely positive.

50% cure rate, or higher, in inoperable spinal tumors and various tumors including adenocarcinoma, adenoid cystic carcinoma, and malignant melanoma that were completely resistant to previous therapy options.
Often Only Four... Thirty-Minute Sessions Needed

Standard radiation or proton therapy often requires 35 or more potentially grueling sessions over three months. Heavy-Ion therapy often only requires four sessions over two weeks. This eliminates dramatic patient suffering.

Heavy-Ion delivers higher amounts of energy to a tumor than an X-ray or proton beam. Sent out on a beam, Heavy-Ions strike tumors with a clustering effect that can overwhelm the tumor’s ability to persist or grow, especially damaging cancer cells at the DNA level.

In conventional X-ray radiotherapy, the radiation dose decreases as the depth of penetration in the body increases. In Heavy-Ion radiotherapy, however, the radiation dose increases with depth to produce a peak (called a Bragg peak) in a finite depth of the body, enabling selective irradiation of cancers.

*Heavy-Ion therapy has minimized side-effects.* It causes dramatically less damage to tissue near the tumor. Treatment is individualized, making it possible to minimize the unnecessary dose to the critical organs such as the spinal cord, brain stem and intestines.
Most Destructive Force on Earth to Kill Deep Tumors

The next generation Cancer Terminator costs about $250 million to build. The construction expenses include the most complex medical machinery ever developed. In one room sits a cyclotron--220 tons of metal. The cyclotron’s magnets and electric fields can accelerate subatomic particles to 60% the speed of light. The Cancer Terminator fires the protons through 100 yards of computer-guided piping into the treatment room. While a patient lies on a bed, a 33-foot-high, 100-ton motorized gantry spins around to zap tumors from the most effective angle.

(A schematic of the next generation of Heavy-Ion therapy. It requires 7,500 square feet and the hardware weighs over 250 tons.)

(Photos: MedAustron)

The first generation of Heavy-Ion facilities were built in Europe and Japan. The next generation Cancer Terminators will be more effective in curing cancer.
Cancer Terminators are Coming to America by 2024

The map shows the institutes that have a strong interest in providing Heavy-Ion therapy if the funds are available. **Exact Locations for the first two Cancer Terminators are scheduled to be announced July 4, 2019.**

We believe seven Cancer Terminators would allow all American cancer patients that would benefit immediate access to this life-saving technology.
We are on the Ground Floor of Introducing a Revolutionary Cancer Cure that will Impact Millions

*Breakthrough Chronic Care* was first introduced to Heavy-Ion therapy when a co-founder with *stage-four* cancer was looking for the best treatment for himself and *Breakthrough* Chronic Care’s cancer patients. He found it with the Cancer Terminator Foundation.

The management of *Breakthrough* Chronic Care was so impressed, they became passionately committed to build Cancer Terminators, not only for their patients’ use, but so every American child and adult cancer patient has access to this revolutionary cure.

*Breakthrough* Chronic Care has successfully reached-out to Fortune 1000 Companies, organizations that represent thousands of small business and churches, the NFL, NBA, Professional Golf and Tennis to participate in *Founding Sponsorships*.

Our Founding Sponsors receive significant new revenues, improved customer and employee loyalty, and create a new generation of visitors to their website. Virtually everyone wants to participate.

“*Breakthrough* Chronic Care is committed to helping The Cancer Terminator Foundation raise 1.5 billion dollars to build Cancer Terminators. A significant percentage of our revenue goes to meet this commitment. Our Founding Sponsors have an unique opportunity to impact this generation and generations to come. We are working on a seven-year plan to build several Cancer Terminators so every American who needs it will have access.”

Jerry Woloszczuk
Co-founder, CFO
*B​reakthrough Chronic Care*
The Foundation Can Arrange Heavy-Ion Therapy Immediately in Vienna, Austria

“American patients don’t need to wait for 2024 for treatment. We can provide immediate access to patients in America. We work closely with the Cancer Terminator Foundation to provide Heavy-Ion therapy to patients as quickly as possible. I am a co-founder of the Cancer Terminator Foundation and this is an important part of our mission.”

Prof. Dr. Eugen B. Hug
Co-Chairman, Cancer Terminator Foundation. Medical Director, MedAustron Ion Therapy Center
Pioneer in Heavy-Ion therapy

“I assist American patients in planning medical trips immediately to Germany or Japan for Heavy-Ion therapy. This includes choosing the correct hospital and physician, right lodging, best airfares and pricing for treatment costs. I can also help with insurance questions. In the future, the Foundation plans to provide financial assistance for those who need it. Please contact me at TheresaG@CancerTerminator.org”

Theresa Gomez,
Patient Travel Concierge, Cancer Terminator Foundation

The MedAustron Ion Therapy Center is one of the most advanced cancer research and treatment facilities in the world. It is on the cutting-edge for treating several cancers with Ion Beam or Particle Therapy. MedAustron is one of a few synchrotron-based facilities worldwide to offer both Proton and Heavy-ion Therapy. Their relationship with the Cancer Terminator Foundation will make their proprietary and advanced treatments to American cancer patients in 2019.
The Cancer Terminator Foundation
A breakthrough cure for incurable cancers!